An observational study in Heart Defects, sponsored by Carelon Research. Active, not recruiting. Open to participants aged 10 Years to 12 Years. Per ClinicalTrials.gov, last updated 2025-11-10.
Sponsored by Carelon Research · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The purpose of this study is to compare direct and indirect measures of right ventricular (RV) systolic and diastolic function between 11 year old subjects who had been randomly assigned to receive a right ventricle to pulmonary artery shunt (RVPAS) vs. a modified Blalock-Taussig shunt (MBTS) at the time of the Norwood operation.
The Single Ventricle Reconstruction (SVR) trial was the first multicenter, randomized clinical trial to compare two operations in the field of congenital heart disease.8,11 Children with HLHS and other related single RV lesions were enrolled and randomized to receive either a MBTS or a RVPAS at the time of the initial Norwood procedure. This landmark study provided extraordinary insight not only into the consequences of both shunt types, but also into the course, treatment responses and short- and mid-term outcomes for these medically complex patients. Through the SVR Trial and SVR Extension Study (SVR II), outcomes, including but not limited to the primary outcome of transplant-free survival, have now been evaluated in this patient cohort when the last enrolled patient reached 12 months and again at 3 years of age. While early post-operative transplant-free survival during the interstage period7 and at one year8 was better for those children randomized to a RVPAS, survival by the 3-year evaluation appeared equivalent between the two shunt types. Moreover, RVEF was somewhat diminished and the number of interventions was higher in the RVPAS group.12 These findings raised concern that the RV dysfunction in the RVPAS group may be progressive, leading to significantly worse long-term outcomes; if so, the benefits of the RVPAS for short-term survival may be outweighed by longer-term morbidity and mortality. Thus, the optimal surgical approach for newborns with HLHS and related single RV lesions remains unclear.
The Pediatric Heart Network (PHN) Investigators have a unique opportunity and responsibility to analyze the effect of the type of systemic-to-pulmonary artery shunt placed during the Norwood procedure on longer-term survival, as well as to define its effect on other long-term outcomes in this multi-institutional cohort of exquisitely characterized subjects with single RV lesions. As subjects enrolled in the SVR cohort approach a decade of age, the investigators aim: 1) to determine if shunt type at the time of Norwood operation is associated with any long-term differences in cardiac function, survival, or contributors to quality of life; and 2) to characterize long-term outcomes and determine risk factors other than shunt type for adverse long-term outcomes in children with HLHS and other related single ventricle anomalies.
Carelon Research is the lead sponsor of 59 studies on the registry; 4 are open to participants now.
Counted across the registry records on this site, refreshed daily.
All SVR study cohort members will be contacted to assess for vital status. Transplant free survivors will be approached to participate in the in-person assessment.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Transplant-free survivors of the SVR cohort (All SVR survivors are eligible to be followed for vital status.)
RVEF at 10-12 Years on MRI
RV ejection fraction (RVEF) at 10-12 years, as measured by cardiac magnetic resonance (CMR).
Time frame: assessed between 10-12 years of age, an average of 53.2 days from consent
Death or Cardiac Transplantation
The incidence of death or cardiac transplantation between those randomized to receive a RVPAS vs. a MBTS at the time of the Norwood operation.
Time frame: 11 years ± 1 year to 16 years
The Exercise Tolerance Between Those Randomized to a RVPAS vs. a MBTS.
Exercise capacity: Maximal Oxygen Consumption (VO2max), maximal work rate, and anaerobic threshold
Time frame: 11 years ± 1 year to 16 years
Atrial and Ventricular Arrhythmias
The incidence of arrhythmias between those randomized to a RVPAS vs. a MBTS.
Time frame: 11 years ± 1 year to 16 years
The Neurodevelopmental Outcomes at 11 Years of Age in Those Randomized to a RVPAS vs. a MBTS
Achievement, as measured by the Wechsler Individual Achievement Tests (WIAT) (Math and Reading); Intelligence, as measured by the Wechsler Intelligence Scale for Children (WISC); Other domains of neurodevelopmental function including assessment of language, executive function, visual spatial skills, motor function, memory, social skills, behavior, health-related quality of life (HRQoL) and adaptive function.
Time frame: 11 years ± 1 year
Risk Stratification Models
Develop risk stratification models for 1) cardiac outcomes, 2) transplant-free survival, and 3) neurodevelopmental outcomes.
Time frame: 11 years ± 1 year to 16 years
Biospecimens
Collect specimens from subjects and their parents to further develop the biologic specimen repository.
Time frame: 11 years ± 1 year to 16 years
| Milestone | mBTTS | RVPAS |
|---|---|---|
| Started | 109 | 128 |
| Completed | 109 | 128 |
| Not completed | 0 | 0 |
RV ejection fraction (RVEF) at 10-12 years, as measured by cardiac magnetic resonance (CMR).
| percentage of blood pumped | mBTTS | RVPAS |
|---|---|---|
| RVEF at 10-12 Years on MRI | 52 ± 7.4 | 51 ± 9.6 |
The incidence of death or cardiac transplantation between those randomized to receive a RVPAS vs. a MBTS at the time of the Norwood operation.
Results for this outcome have not been posted.
Exercise capacity: Maximal Oxygen Consumption (VO2max), maximal work rate, and anaerobic threshold
Results for this outcome have not been posted.
The incidence of arrhythmias between those randomized to a RVPAS vs. a MBTS.
Results for this outcome have not been posted.
Achievement, as measured by the Wechsler Individual Achievement Tests (WIAT) (Math and Reading); Intelligence, as measured by the Wechsler Intelligence Scale for Children (WISC); Other domains of neurodevelopmental function including assessment of language, executive function, visual spatial skills, motor function, memory, social skills, behavior, health-related quality of life (HRQoL) and adaptive function.
Results for this outcome have not been posted.
Develop risk stratification models for 1) cardiac outcomes, 2) transplant-free survival, and 3) neurodevelopmental outcomes.
Results for this outcome have not been posted.
Collect specimens from subjects and their parents to further develop the biologic specimen repository.
Results for this outcome have not been posted.
Collected over through study completion, an average of 5.3 years from consent. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| mBTTS | 3/109 (2.8%) | 0/109 (0%) | 0/109 (0%) |
| RVPAS | 3/128 (2.3%) | 0/128 (0%) | 0/128 (0%) |
| Age, Categorical(Participants) | mBTTS | RVPAS | Total |
|---|---|---|---|
| <=18 years | 109 | 128 | 237 |
| Between 18 and 65 years | 0 | 0 | 0 |
| >=65 years | 0 | 0 | 0 |
| Sex: Female, Male(Participants) | mBTTS | RVPAS | Total |
|---|---|---|---|
| Female | 47 | 46 | 93 |
| Male | 62 | 82 | 144 |
| Ethnicity (NIH/OMB)(Participants) | mBTTS | RVPAS | Total |
|---|---|---|---|
| Hispanic or Latino | 14 | 27 | 41 |
| Not Hispanic or Latino | 95 | 100 | 195 |
| Unknown or Not Reported | 0 | 1 | 1 |
| Race/Ethnicity, Customized(Participants) | mBTTS | RVPAS | Total |
|---|---|---|---|
| White | 95 | 106 | 201 |
| Non-White | 13 | 21 | 34 |
| Missing | 1 | 1 | 2 |
No study locations are listed for this record.
PDFs hosted by the registry, ClinicalTrials.gov.
The record gives a start of Jun 2015, a primary completion of Oct 2020 and a completion of Dec 2025. It does not say whether these dates are actual or estimated.
Results were first posted in Nov 2025, 5 years 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is active, not recruiting, as verified in Mar 2025. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Carelon Research